Inc. Cerecor Net Worth

The estimated Net Worth of Inc. Cerecor is at least $24.5 Milion dollars as of 15 April 2020. Inc Cerecor owns over 92,777 units of Aytu BioPharma Inc stock worth over $24,379,801 and over the last 5 years Inc sold AYTU stock worth over $143,804.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Inc Cerecor AYTU stock SEC Form 4 insiders trading

Inc has made over 1 trades of the Aytu BioPharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Inc sold 92,777 units of AYTU stock worth $143,804 on 15 April 2020.

The largest trade Inc's ever made was selling 92,777 units of Aytu BioPharma Inc stock on 15 April 2020 worth over $143,804. On average, Inc trades about 92,777 units every 0 days since 2020. As of 15 April 2020 Inc still owns at least 9,713,068 units of Aytu BioPharma Inc stock.

You can see the complete history of Inc Cerecor stock trades at the bottom of the page.

What's Inc Cerecor's mailing address?

Inc's mailing address filed with the SEC is 540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850.

Insiders trading at Aytu BioPharma Inc

Over the last 9 years, insiders at Aytu BioPharma Inc have traded over $40,722,795 worth of Aytu BioPharma Inc stock and bought 8,465,326 units worth $11,497,374 . The most active insiders traders include Capital, Llc Armistice Capi..., Carl Dockery oraz Joshua R. Disbrow. On average, Aytu BioPharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,701,531. The most recent stock trade was executed by Greg Pyszczymuka on 30 June 2024, trading 208 units of AYTU stock currently worth $522.

What does Aytu BioPharma Inc do?

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.

Complete history of Inc Cerecor stock trades at Aytu BioPharma Inc

Aytu BioPharma Inc executives and stock owners

Aytu BioPharma Inc executives and other stock owners filed with the SEC include:

• Joshua Disbrow,
  Chairman of the Board, Chief Executive Officer
• Joshua R. Disbrow,
  Chairman & CEO
• Jarrett Disbrow,
  Chief Operating Officer
• David Green,
  Chief Financial Officer, Treasurer, Secretary
• Michael Macaluso,
  Independent Director
• John Donofrio,
  Independent Director
• Carl Dockery,
  Independent Director
• Gary Cantrell,
  Independent Director
• Ketan Mehta,
  Director
• James Carbonara,
  IR Contact Officer
• Steven Boyd,
  Director
• Matthew Phillips,
  Executive Vice President - Commercial Operations
• Russ McMahen,
  Sr. VP of R&D
• Topher Brooke,
  Exec. VP of Rare Disease Devel.
• Nate Massari,
  Exec. VP of Rare Disease Operations
• Greg Pyszczymuka,
  Chief Commercial Officer
• Jarrett T. Disbrow Ph.D.,
  Exec. VP of Corp. Operations
• Beth Hecht,
  Director
• Gerald W. Mc Laughlin,
  Director
• Inc. Cerecor,
  10% owner
• Capital Management, Llc Har...,
  
• Gregory A Gould,
  Chief Financial Officer
• Jonathan H Mc Grael,
  Vice President of Sales
• Pharmaceuticals, Inc. Ampio,
  10% owner
• Mark K Oki,
  Chief Financial Officer
• Greg Pyszczymuka,
  Chief Commercial Officer
• Christopher Brooke,
  Chief Operating Officer
• Abhinav Jain,
  
• Vivian H Liu,
  
• Richard I Eisenstadt,
  Chief Financial Officer